Results 11 to 20 of about 42,426 (185)
Current Therapeutic Research, 2020 : Background: Parkinson's disease is a neurodegenerative disorder, and a major cause of disability. Levodopa, a prodrug of dopamine, remains the gold standard in the pharmacological management of Parkinson's disease.
Benedicta Obenewaa Dankyi, MPhil +5 more
doaj +1 more source
Cells, 2022 The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller +3 more
doaj +1 more source
Levodopa-induced pseudopheochromocytoma
European Journal of Case Reports in Internal Medicine, 2023 Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso +6 more
openaire +3 more sources
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Frontiers in Neurology, 2021 Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios +9 more
doaj +1 more source
Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase
npj Parkinson's Disease, 2021 Peripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed
Anouke van Rumund +8 more
doaj +1 more source
Experience in using levodopa-benserazide
Неврология, нейропсихиатрия, психосоматика, 2015 Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina +3 more
doaj +1 more source
Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes
Frontiers in Neurology, 2021 Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li +7 more
doaj +1 more source
ADMET and DMPK, 2022 Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah +8 more
doaj +1 more source
Therapeutic Advances in Chronic Disease, 2019 Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra +9 more
doaj +1 more source
Effects of levodopa on gut bacterial antibiotic resistance in Parkinson’s disease rat
Frontiers in Aging Neuroscience, 2023 The second most prevalent neurodegenerative ailment, Parkinson’s disease (PD), is characterized by both motor and non-motor symptoms. Levodopa is the backbone of treatment for PD at the moment.
Shuo Sheng +6 more
doaj +1 more source